* TFF Pharmaceuticals Inc reported a quarterly adjusted loss of $1.22 per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-3.50. The lone analyst forecast for the quarter was for a loss of $1.70 per share.
* Revenue rose 95.2% to $650.00 thousand from a year ago; analysts expected $150.00 thousand.
* TFF Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.22.
* The company reported a quarterly loss of $4.48 million.
* TFF Pharmaceuticals Inc shares had risen by 22.9% this quarter and lost 70.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 4.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for TFF Pharmaceuticals Inc is $30.00 This summary was machine generated from LSEG data August 15 at 05:19 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -1.70 -1.22 Beat
Mar. 31 2024 -2.26 -2.40 Missed
Dec. 31 2023 -2.01
Sep. 30 2023 -2.25
Comments